<International Circulation>: Could you talk about the main improvements in studies in the last 15 years and why we can see more precise results? 
    Prof. Kjeldsen: We have better protocols， larger sample sizes， better statistical power and better follow-up. There is much less discontinuation in these mass clinical trials. We get better precision. Differences are not overwhelming， but we get statistical significance.

    <International Circulation>:  In ACCOMPLISH， the biggest difference was the drop in cardiovascular endpoint in patients taking the CCB ACE inhibitor? 
    Prof. Kjeldsen:Yes， that’s right. There was a 20% reduction in the primary cardiovascular endpoint.